PROTOKINETIX, INCORPORATED

PKTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-393.7K $-364.2K $-415.5K $-1.9M $-2.3M $-7.6M $-4.2M $-1.2M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — — —
Amortization $51.3K $52.9K $48.3K $58.5K $3.0K $3.0K $3.0K $3.0K
Stock-Based Compensation $0 $5.4K $0 $1.1M $1.4M $6.7M $3.4M $648.8K
Net Cash from Operating Activities $-135.4K $-223.1K $-376.0K $-804.7K $-889.9K $-881.3K $-850.7K $-453.5K
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-56.3K $-58.1K $-59.2K $-132.0K $-91.0K $-70.2K $-25.0K $-35.5K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $197.5K $256.0K $430.0K $904.7K $845.0K $767.6K $1.1M $322.0K
Net Change in Cash — — — — — $-183.9K $241.3K $-166.9K
Free Cash Flow — — — — — — — —
← Newer Page 1 of 2 Older →